Table 4.

Mothers’ (a) and infants’ (b) pre dose 1 serum rotavirus-IgG by infants’ rotavirus vaccines IgA seroconversion^a.

Reference	Location	Income groupd	Vaccine	No of Doses	Measured factors	Rotavirus vaccines IgA seroconversion		p-Value
						R	NR
Becker-Dreps 2015 [58]	Nicaragua	LM	RV5	1	Mothers’ pre dose 1 sera RV-IgG, median (IQR)	2560 [4360, 5119]	5120 [3119, 12,240]	0.020
Rongsen-Chandola et al. 2014 [55]	India	LM	RV1	2	Mothers’ pre dose 1 sera RV-IgG, OR (95% CI)	0.75 (0.60–0.93)	Ref	0.011
Moon et al. 2016 [57]	South Africa	UM	RV1	1	Mothers’ pre dose 1 sera RV-IgG, median (IQR)	5120 (80–81 920)	10,240 (640–163,840)	0.031
				2		10,240 (80–163,840)	10,240 (640–163,840)	NS
Appaiahgari et al. 2014 [67]	India	LM	116E	2	Infants’ pre dose 1 sera RV-IgG, Median AU/ml [range]	7278 [1121–48,532]	15,243 [3742–84,360]	<0.001
Becker-Dreps 2015 [58]	Nicaragua	LM	RV5	1	Infants’ pre dose 1 sera RV-IgG, median (IQR)	1280 [640–4560]	560 [1280–3119]	NS
Chilengi et al. 2016 [56]	Zambia	LM	RV1	2	Infants’ pre dose 1 sera RV-IgG, GMT (95% CI)	3988 (3340–4762)	4833 (3998–5842)	NS
Moon et al. 2016 [56]	South Africa	UM	RV1	1	Infants’ pre dose 1 sera RV-IgG, median (IQR)	1280 (20–10,240)	1280 (80–20,480)	0.010
				2		1280 (20–10,240)	1280 (80–20,480)	0.072
Chen et al. 2017 [59]	New Zealand	H	RV3-BB	3	Neonatal scheduleb: Infants’ pre dose 1 sera RV-IgG, Units median (range)	18,599 (7169–29,223)	28,437 (26,397–34,566)	NS
					Infant schedulec: Infants’ pre dose 1 sera RV-IgG, Units median (range)	15,879 (8485–29,157)	31,100 (24,303–41,746)	NS

RV: rotavirus; R: responders; NR: non responders; NS: non-statistically significant (p > 0.10); IQR: interquartile range; RV1: rotarix; RV5: rotateq; RV3-BB: live attenuated neonatal rotavirus strain, G3P[7].

^aStudies that analyzed mother–infant pairs

^bDoses administered at 0, 8, 15 weeks of age

^cDoses administered at 8, 15, 24 weeks of age;

^dWorld Bank list of economies (December 2016) low-income (L); lower middle-income (LM); upper middle-income (UM); high-income (H).